Table 2 Classification based on 2016, 2022 World Health Organization classification and International Consensus Classification.

From: Prognostic implications of genetic and transcriptomic abnormalities in MDS according to IPSS-R, IPSS-M, and the International Consensus Classification

Classification

Total (n = 758)

Without cytogenetics abnormalities and gene mutations (n = 155/20.4%)

With gene mutations only (n = 299/39.4%)

With cytogenetics abnormalities only (n = 62/8.2%)

With cytogenetics abnormalities and gene mutations (n = 242/31.9%)

P value

2016 WHO classification

 MDS-5q

7 (0.9)

0 (0.0)

0 (0.0)

1 (1.6)

6 (2.5)

0.004

 MDS-SLD

114 (15.0)

60 (38.7)

33 (11.0)

13 (21.0)

8 (3.3)

<0.001

 MDS-MLD

166 (21.9)

65 (41.9)

46 (15.4)

23 (37.1)

32 (13.2)

<0.001

 MDS-RS-SLD

46 (6.1)

4 (2.6)

31 (10.4)

1 (1.6)

10 (4.1)

0.001

 MDS-RS-MLD

26 (3.4)

2 (1.3)

15 (5.0)

1 (1.6)

8 (3.3)

0.194

 MDS-EB1

160 (21.1)

16 (10.3)

68 (22.7)

15 (24.2)

61 (25.2)

0.003

 MDS-EB2

230 (30.3)

6 (3.9)

101 (33.8)

8 (12.9)

115 (47.5)

<0.001

 MDS-U

9 (1.2)

2 (1.3)

5 (1.7)

0 (0.0)

2 (0.8)

0.759

ICC

 MDS

561 (74.0)

149 (96.1)

210 (73.4)

55 (88.7)

147 (61.5)

<0.001

 del(5q)

5 (0.7)

0 (0.0)

0 (0.0)

1 (1.6)

4 (1.7)

0.007

 mutated SF3B1

64 (8.4)

0 (0.0)

49 (16.4)

0 (0.0)

15 (6.2)

<0.001

 NOS, with SLD

124 (16.4)

66 (42.6)

35 (11.7)

14 (22.6)

9 (3.7)

<0.001

 NOS, with MLD

169 (22.3)

67 (43.2)

46 (15.4)

24 (38.7)

32 (13.2)

<0.001

 EB

171 (22.6)

16 (10.3)

79 (26.4)

16 (25.8)

60 (24.8)

<0.001

 mutated TP53

28 (3.7)

0 (0.0)

2 (0.6)

0 (0.0)

26 (12.0)

<0.001

 MDS/AML

181 (23.9)

6 (3.9)

76 (26.6)

7 (11.3)

92 (38.5)

<0.001

 MDS-related genes mutations

98 (12.9)

0 (0.0)

54 (18.1)

0 (0.0)

44 (18.2)

<0.001

 MDS-related cytogenetics

11 (1.5)

0 (0.0)

0 (0.0)

5 (8.1)

6 (2.5)

<0.001

 mutated TP53

44 (5.8)

0 (0.0)

4 (1.3)

0 (0.0)

40 (16.5)

<0.001

 NOS

28 (3.7)

6 (3.9)

18 (6.0)

2 (3.2)

2 (0.8)

0.008

 AML with NPM1

13 (1.7)

0 (0.0)

11 (3.7)

0 (0.0)

2 (0.8)

0.014

 AML with CEBPA

2 (0.3)

0 (0.0)

2 (0.7)

0 (0.0)

0 (0.0)

0.586

 AML with inv(3)

1 (0.1)

0 (0.0)

0 (0.0)

0 (0.0)

1 (0.4)

0.606

2022 WHO classification

737

     

 MDS-5q

5 (0.7)

0 (0.0)

0 (0.0)

1 (1.6)

4 (1.7)

0.008

 MDS-SF3B1

82 (11.1)

0 (0.0)

50 (17.7)

0 (0.0)

18 (7.4)

<0.001

 MDS-h

114 (15.5)

58 (52.3)

25 (8.9)

19 (30.6)

12 (5.0)

<0.001

 MDS-LB

156 (21.2)

31 (27.9)

52 (18.4)

19 (30.6)

28 (11.6)

<0.001

 MDS-IB1

118 (16.0)

16 (14.4)

51 (18.1)

14 (22.6)

37 (15.3)

0.083

 MDS-IB2

159 (21.6)

5 (4.5)

78 (27.7)

7 (11.3)

69 (28.5)

<0.001

 MDS-f

24 (3.3)

1 (0.9)

5 (1.8)

1 (1.6)

17 (7.0)

0.001

 MDS-biTP53

46 (6.2)

0 (0.0)

2 (0.7)

0 (0.0)

44 (18.2)

<0.001

 AML with NPM1 mutation

23 (3.1)

0 (0.0)

19 (6.7)

0 (0.0)

4 (1.7)

<0.001

 AML with MECOM rearrangement

1 (0.1)

0 (0.0)

0 (0.0)

0 (0.0)

1 (0.4)

0.617

 AML with NUP98 rearrangement

9 (1.2)

0 (0.0)

0 (0.0)

1 (1.6)

8 (3.3)

0.001

  1. P values of <0.05 are statistically significant.
  2. Data are presented as n (%).
  3. ICC International Consensus Classification, MDS-RS MDS with ring sideroblasts, MDS-EB MDS with excess blasts, MDS-SLD MDS with single lineage dysplasia, MDS-MLD MDS with multilineage dysplasia, MDS-RS-SLD MDS with ring sideroblasts and single lineage dysplasia, MDS-RS-MLD MDS with ring sideroblasts and multilineage dysplasia, MDS-U MDS unclassifiable, MDS-5q MDS with low blasts and isolated 5q deletion, MDS-SF3B1 MDS with low blasts and SF3B1 mutation, MDS-LB and RS MDS with low blasts and ring sideroblasts, MDS-LB MDS with low blasts; MDS-h, hypoplastic MDS, MDS-IB1 MDS with increased blasts-1, MDS-IB2 MDS with increased blasts-2, MDS-f MDS with fibrosis, MDS-biTP53 MDS with biallelic TP53 inactivation, NOS not otherwise specified.
Back to article page